X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MarVax is a subunit protein vaccine of recombinantly expressed Marburg marburgvirus (MARV) glycoprotein, which is being evaluated for the prevention and post-exposure prophylaxis against MARV infection.
Lead Product(s): Marburg Marburgvirus Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: MarVax
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Dr. Axel Lehrer
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
SuVax is a subunit protein vaccine of recombinantly expressed Sudan Ebola virus glycoprotein, which is indicated for the prevention and post-exposure prophylaxis against SUDV infection.
Lead Product(s): Sudan Ebola Virus Glycoprotein
Therapeutic Area: Infections and Infectious Diseases Product Name: Suvax
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
SGX945 (dusquetide) is an innate defense regulator (p62 protein modulator), a new class of short, synthetic peptides. It is being evaluated for the treatment of lesions of Behçet's Disease
Lead Product(s): Dusquetide
Therapeutic Area: Rare Diseases and Disorders Product Name: SGX945
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
SGX945 (dusquetide) is an innate defense regulator (IDR), a new class of short, synthetic peptides. It is being evaluated in IND enabling studies for the treatment of oral lesions of Behçet's Disease.
Lead Product(s): Dusquetide
Therapeutic Area: Rare Diseases and Disorders Product Name: SGX945
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
SGX302 (synthetic hypericin) is a novel, first-in-class, photodynamic therapy (PDT) that is expected to avoid many of the long-term risks associated with other PDT treatments. It is under phase 2 clinical development for the treatment of mild-to-moderate psoriasis.
Lead Product(s): Hypericin
Therapeutic Area: Dermatology Product Name: SGX302
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
SGX945 (dusquetide) is a peptide inhibitor administered intravenously via infusion, which is being investigated for treating Aphthous Ulcers in Behçet's Disease.
Lead Product(s): Dusquetide
Therapeutic Area: Rare Diseases and Disorders Product Name: SGX945
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
HyBryte (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light, it demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients.
Lead Product(s): Hypericin Sodium
Therapeutic Area: Oncology Product Name: HyBryte
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
SGX302 (synthetic hypericin) is absorbed by cells in the treated skin and can then be activated by fluorescent light, which is investigated for the treatment of mild-to-moderate psoriasis.
Lead Product(s): Synthetic Hypericin
Therapeutic Area: Dermatology Product Name: SGX302
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
SGX942 (dusquetide) is an innate defense regulator (IDR), short synthetic peptides, which modulates the body's reaction to both injury and infection towards an anti-inflammatory, anti-infective and tissue healing response in conditions like oral mucositis.
Lead Product(s): Dusquetide
Therapeutic Area: Immunology Product Name: SGX942
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
HyBryte (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light, it demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients.
Lead Product(s): Hypericin Sodium
Therapeutic Area: Oncology Product Name: HyBryte
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
